Reducing this ratio can facilitate BIM-dependent cell death, as documented before in mature B cells exposed to SYK inhibitor that blocks BCR-dependent A1 expression.14 Along these lines, recent evidence uncovered that high expression of A1/BFL-1 mediates drug resistance to BRAF inhibitors that have also been shown to act in part by stabilizing BIM levels in human melanoma.11 Hence, the ratio between A1 and BIM may be decisive how well malignant cells can respond to therapy. Here, BCL2L11 is linked to melanoma.